DKK 0.08
(-12.45%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | - DKK | 0.0% |
2022 | - DKK | 0.0% |
2021 | - DKK | 0.0% |
2020 | - DKK | 0.0% |
2019 | - DKK | 0.0% |
2018 | - DKK | 0.0% |
2017 | - DKK | -100.0% |
2016 | 1.05 Million DKK | 70.0% |
2015 | 620 Thousand DKK | 0.0% |
2014 | - DKK | 0.0% |
2013 | - DKK | -100.0% |
2012 | 13.25 Million DKK | -14.43% |
2011 | 15.48 Million DKK | 2895.36% |
2010 | 517 Thousand DKK | 0.0% |
2009 | - DKK | 0.0% |
2008 | - DKK | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | - DKK | 0.0% |
2024 Q2 | - DKK | 0.0% |
2023 Q4 | - DKK | 0.0% |
2023 Q1 | - DKK | 0.0% |
2023 Q2 | - DKK | 0.0% |
2023 Q3 | - DKK | 0.0% |
2023 FY | - DKK | 0.0% |
2022 Q4 | - DKK | 0.0% |
2022 FY | - DKK | 0.0% |
2022 Q2 | - DKK | 0.0% |
2022 Q3 | - DKK | 0.0% |
2021 FY | - DKK | 0.0% |
2020 FY | - DKK | 0.0% |
2019 FY | - DKK | 0.0% |
2018 FY | - DKK | 0.0% |
2017 FY | - DKK | -100.0% |
2016 Q1 | 281 Thousand DKK | -39.44% |
2016 FY | 1.05 Million DKK | 70.0% |
2016 Q2 | 258 Thousand DKK | -8.19% |
2015 FY | 620 Thousand DKK | 0.0% |
2015 Q4 | 464 Thousand DKK | 197.44% |
2015 Q3 | 156 Thousand DKK | 0.0% |
2015 Q2 | - DKK | 0.0% |
2015 Q1 | - DKK | -100.0% |
2014 Q4 | 12 Thousand DKK | 0.0% |
2014 Q1 | - DKK | -100.0% |
2014 FY | - DKK | 0.0% |
2014 Q2 | - DKK | 0.0% |
2014 Q3 | - DKK | 0.0% |
2013 Q2 | - DKK | 0.0% |
2013 Q4 | 38.24 Million DKK | 0.0% |
2013 Q3 | - DKK | 0.0% |
2013 Q1 | - DKK | -100.0% |
2013 FY | - DKK | -100.0% |
2012 Q3 | 3.14 Million DKK | -6.34% |
2012 Q2 | 3.35 Million DKK | 8.99% |
2012 FY | 13.25 Million DKK | -14.43% |
2012 Q1 | 3.08 Million DKK | -20.01% |
2012 Q4 | 3.15 Million DKK | 0.22% |
2011 Q2 | 3.8 Million DKK | -3.33% |
2011 Q3 | 3.88 Million DKK | 2.13% |
2011 FY | 15.48 Million DKK | 2895.36% |
2011 Q1 | 3.93 Million DKK | 661.7% |
2011 Q4 | 3.85 Million DKK | -0.9% |
2010 FY | 517 Thousand DKK | 0.0% |
2010 Q4 | 517 Thousand DKK | 0.0% |
2010 Q3 | - DKK | 0.0% |
2010 Q2 | - DKK | 0.0% |
2010 Q1 | - DKK | 0.0% |
2009 Q2 | - DKK | 0.0% |
2009 Q3 | - DKK | 0.0% |
2009 FY | - DKK | 0.0% |
2009 Q4 | - DKK | 0.0% |
2008 FY | - DKK | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
ALK-Abelló A/S | 4.82 Billion DKK | 100.0% |
Bavarian Nordic A/S | 7.05 Billion DKK | 100.0% |
Genmab A/S | 16.47 Billion DKK | 100.0% |
Gubra A/S | 205 Million DKK | 100.0% |
Novo Nordisk A/S | 232.26 Billion DKK | 100.0% |
Orphazyme A/S | - DKK | NaN% |
Zealand Pharma A/S | 342.78 Million DKK | 100.0% |